Scientific Letters
Vol. 18 No. 1 (2026): Mediterranean Journal of Hematology and Infectious Diseases
https://doi.org/10.4084/MJHID.2026.052

Sarcoid-like Reactions in Hodgkin Lymphoma Treated with Pembrolizumab: a Case Report

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: June 30, 2026
0
Views
0
Downloads
0
HTML

Authors

Pier Luigi Zinzani
pierluigi.zinzani@unibo.it
{"en_US":"Institute of Hematology “L. e A. Seràgnoli”, University of Bologna"}, Italy.
Flavia Salvatore
Beatrice Casadei
Camilla Mazzoni
Marianna Gentilini
Giulia Gabrielli
Lisa Argnani
https://orcid.org/0000-0003-4225-4626
Immune checkpoint inhibitors have significantly improved outcomes in relapsed or refractory Hodgkin lymphoma (rrHL). Pembrolizumab, a programmed death-1 inhibitor, is generally well tolerated but may induce immune-related adverse events (irAE), including rare sarcoid-like reactions that can mimic disease progression. We report the case of a 30-year-old woman with refractory classical Hodgkin lymphoma (cHL) who developed pulmonary sarcoid-like granulomatous inflammation during pembrolizumab therapy. 

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
[1]. Ansell SM. Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024 Dec;99(12):2367-2378. doi: 10.1002/ajh.27470. Epub 2024 Sep 6. PMID: 39239794
[2]. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22. Erratum in: Leukemia. 2023 Sep;37(9):1944-1951. doi: 10.1038/s41375-023-01962-5. PMID: 35732829; PMCID: PMC9214472.
[3]. Dalton M Craven, Meagan J Harrington, Griffin M Sansbury, Tarsizious Chikaonda, Marriam Mponda, Claire T Pedersen, Karen S Grigg, Hannah Burrows, Matthew S Painschab. Hodgkin lymphoma treatment patterns and outcome disparities in low- and middle-income countries: A systematic review. Blood Global Hematology, 2025. 100021, ISSN 3050-5658. doi.org/10.1016/j.bglo.2025.100021.
[4]. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol. 2016 Nov 1;34(31):3733-3739. doi: 10.1200/JCO.2016.67.3467. PMID: 27354476; PMCID: PMC5791838.
[5]. Naleid N, Mahipal A, Chakrabarti S. Toxicity Associated with Pembrolizumab Monotherapy in Patients with Gastrointestinal Cancers: A Systematic Review of Clinical Trials. Biomedicines. 2025 Jan 18;13(1):229. doi: 10.3390/biomedicines13010229. PMID: 39857812; PMCID: PMC11762711.
[6]. Boucheron T, Chiche L, Penaranda G, Souquet M, Pegliasco H, Deturmeny J, Brunel V, Barrière N, Arbault-Bitton C, Coquet E, Diaz L, Escoda T. Risk of Serious Immune-Related Adverse Events with Various PD1 and PD-L1 Inhibitors: A Single-Institution, Real-Life, Comparative Study. Ther Clin Risk Manag. 2025 Mar 5;21:273-282. doi: 10.2147/TCRM.S479686. PMID: 40060169; PMCID: PMC11890422.
[7]. Baraka, B., Abosheaishaa, H. & Nassar, M. Immunotherapy-induced thyroid dysfunction: an updated review. Egypt J Intern Med 35, 48 (2023). https://doi.org/10.1186/s43162-023-00210-7
[8]. Furrer-Matcau C, Sieber C, Lehnick D, Brand CU, Hug B. Cutaneous adverse events due to checkpoint inhibitors - a retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022. Front Oncol. 2024 Dec 5;14:1485594. doi: 10.3389/fonc.2024.1485594. PMID: 39703836; PMCID: PMC11655322.
[9]. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Dec 1;2(12):1607-1616. doi: 10.1001/jamaoncol.2016.2453. PMID: 27540850.
[10]. Argnani L, Stefoni V, Casadei B, Pelusi C, Preiato VL, Pagotto U, Buganè A, Pellegrini C, Broccoli A, Zinzani PL. Immune-related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors. Br J Haematol. 2026 Feb 26. doi: 10.1111/bjh.70402. Epub ahead of print. PMID: 41744197.
[11]. Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA, Syrigos KN. Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors. J Thorac Oncol. 2018 Aug;13(8):1076-1082. doi: 10.1016/j.jtho.2018.04.031. Epub 2018 May 12. PMID: 29763666.
[12]. Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Fogliatto LM, Goncalves I, de Oliveira JSR, Buccheri V, Perini GF, Goldschmidt N, Kriachok I, Dickinson M, Komarnicki M, McDonald A, Ozcan M, Sekiguchi N, Zhu Y, Nahar A, Marinello P, Zinzani PL; KEYNOTE-204 investigators. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021 Apr;22(4):512-524. doi: 10.1016/S1470-2045(21)00005-X. Epub 2021 Mar 12. Erratum in: Lancet Oncol. 2021 May;22(5):e184. doi: 10.1016/S1470-2045(21)00193-5. PMID: 33721562.
[13]. Yousuf H, Mekki R, Khan K, Hussain A. Pembrolizumab-Induced Sarcoid-Like Reaction in a Patient With Lung Cancer. Cureus. 2020 Dec 31;12(12):e12395. doi: 10.7759/cureus.12395. PMID: 33409108; PMCID: PMC7779128.
[14]. Li Y, Flavell RR, Juarez R, Chow M, Wu C, Tsai K, Daud A, Behr SC. Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy. Clin Radiol. 2023 Feb;78(2):e131-e136. doi: 10.1016/j.crad.2022.09.127. Epub 2022 Nov 4. PMID: 36344282.
[15]. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1. Erratum in: J Clin Oncol. 2022 Jan 20;40(3):315. doi: 10.1200/JCO.21.02786. PMID: 34724392.
[16]. Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-1238. doi: 10.1016/j.annonc.2022.10.001. Epub 2022 Oct 18. PMID: 36270461.
[17]. O'Kane GM, Labbé C, Doherty MK, Young K, Albaba H, Leighl NB: Monitoring and management of immunerelated adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer. Oncologist. 2017, 22:70-80
[18]. Gayá García-Manso I, García Ródenas MDM, Barroso Medel ME, Illán Gambín FJ. Sarcoidosis-Like Granulomatous Reaction Associated With Pembrolizumab Immunotherapy. Arch Bronconeumol (Engl Ed). 2018 Nov;54(11):592-593. English, Spanish. doi: 10.1016/j.arbres.2018.04.010. Epub 2018 May 22. PMID: 29801680.

How to Cite



“Sarcoid-like Reactions in Hodgkin Lymphoma Treated with Pembrolizumab: a Case Report” (2026) Mediterranean Journal of Hematology and Infectious Diseases, 18(1), p. e2026052. doi:10.4084/MJHID.2026.052.
Copyright (c) 2026 Pier Luigi Zinzani, Flavia Salvatore, Beatrice Casadei, Camilla Mazzoni, Marianna Gentilini, Giulia Gabrielli, Lisa Argnani Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.